Is OrthoPediatrics Corp. (KIDS) Overvalued?
We dive into why OrthoPediatrics Corp. (KIDS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Stock Evaluator: OrthoPediatrics Corp. (KIDS)
OrthoPediatrics Corp. KIDS
$25.65
-0.58
-2.21%
August 21, 2026 4:00:00 PM
EST
Volume: 364,622
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Commentary & Analysis
What You Need to Know About OrthoPediatrics Corp.'s Q3 Earnings
OrthoPediatrics Corp.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (KIDS) missed or beat analyst's expectations.Tudor Pop
Why OrthoPediatrics Corp.’s (KIDS) Stock Is Down 5.72%
As of Tuesday, July 14, OrthoPediatrics Corp.’s KIDS share price has dipped by 5.72%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why OrthoPediatrics Corp.’s (KIDS) Stock Is Down 5.88%
As of Tuesday, June 30, OrthoPediatrics Corp.’s KIDS share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Why OrthoPediatrics Corp.’s (KIDS) Stock Is Up 5.67%
As of Thursday, June 04, OrthoPediatrics Corp.’s KIDS share price has surged by 5.67%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | KIDS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $669.7 | $422.9 | 40% |
|
| Shares Out (Mil) | 24.0 | 41.4 | 33% |
|
| Institutional Ownership | 91.0% | 83.6% | 59% |
|
| Float (Mil) | 17.5 | 34.9 | 27% |
|
| Beta | 0.96 | 0.88 | 58% |
|
| Avg Daily Volume (000s) | 236 | 409 | 46% |
|
| Price Change (52-week) |
31.7% | 66.3% | 69% |
|
| Growth | KIDS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 27.2% | 11.9% | 88% |
|
| Net Income (5yr) | (3.8%) | (5.9%) | 35% |
|
| EPS (5yr) | 1.5% | 10.4% | 33 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.0% | (16.2%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 4 | 6 | |
| Current EPS | ($0.215) | ($1.093) | ($0.710) | |
| Month Ago EPS | ($0.170) | ($1.052) | ($0.680) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.170) | ($1.052) | ($0.680) | |
| Year/Year Chg | (27.9%) | (35.3%) | (84.0%) | |
| Financials | KIDS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $253 | $123 | 34% |
|
| Net Income (TTM) (Mil) | ($40) | ($9) | 18% |
|
| EPS (TTM) | ($1.675) | ($0.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | $7 | ($3) | 37% |
|
| Net Cash Flow (TTM) (Mil) | ($28) | $1 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $109 | $22 | 45% |
|
| Enterprise Value (Q1) (Mil) | $661 | $418 | 37% |
|
| Valuation | KIDS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.95 | 3.13 | 49% |
|
| P/E | na | 28.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | KIDS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.7% | 58.7% | 84% |
|
| Net Margin | (15.7%) | (6.9%) | 18% |
|
| ROA | (7.8%) | (12.3%) | 27% |
|
| ROE | (11.4%) | (12.3%) | 27% |
|
| Liabilities to Assets | 32.8% | 46.0% | 24% |
|
| F-Score | 6 | 4 | 67% |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
